Entera Bio Ltd (ENTX)

$HYFT : Positioned in an $8B+ Global Vaccine Opportunity 💰 MindWalk Holdings Corp. delivered strong growth in its latest quarterly earnings, reinforcing confidence in its Bio-Native AI strategy and adding fuel to growing momentum in the stock. Latest earnings highlights: 🔹 Revenue up 54% YoY to $4.1M, a record quarterly result 🔹 Gross profit up 94%, with margins expanding to ~65% 🔹 Operating loss narrowed, reflecting improving efficiency 🔹 ~$16.5M in cash, supporting continued program advancement These results point to rising demand for MindWalk’s HYFT Deep Data and LensAI platform, alongside disciplined, capital-efficient execution. Backed by recent scientific breakthroughs, $HYFT is gaining visibility and momentum as platform validation continues to resonate with the market. Execution is strengthening, momentum is building, and the setup ahead looks compelling. 📈 Communicated Disclaimer: https://bit.ly/45yIR8a Sector Peers: $CRSP $ABCL $CABA $ENTX

$ENTX https://insights.citeline.com/pink-sheet/pathways-and-standards/review-pathways/osteoporosis-drug-development-boosted-by-new-bone-mineral-density-surrogate-endpoint-63XY2JYTYZH5RAQXNHDQ7GKAH4/ Key quote from new citeline article featuring Entera - "Now that the agency has decided not to unilaterally require quantitative thresholds for efficacy, Entera is further streamlining the study’s design, Toledano said. Key Takeaways - - The FD A qualified the percentage change from baseline at 24 months in total hip bone mineral density as a validated surrogate endpoint for regular approval of drugs to treat post-menopausal women with osteoporosis. - The endpoint qualification package included patient-level data from 52 clinical trials and showed the importance of partnerships in successfully navigating the FDA process. - The qualification decision will allow Entera Bio, which is developing an oral version of teriparatide, to further simplify its planned Phase III trial. The FDA determination letter contains “real black and white simplifications” and “has given us an opportunity to further simplify our plan,” she said. For example, the company had been planning to include a secondary endpoint of correlation between BMD and fracture. In light of the FD A’s qualification determination, “there is no need for that secondary endpoint. Total hip BMD is a surrogate,” Toledano said." https://insights.citeline.com/pink-sheet/pathways-and-standards/review-pathways/osteoporosis-drug-development-boosted-by-new-bone-mineral-density-surrogate-endpoint-63XY2JYTYZH5RAQXNHDQ7GKAH4/

📌 $HYFT : Weekly Chart Setting Up for Expansion MindWalk holdings is pressing into key weekly resistance near $3.25, aligning with the cup level on the weekly timeframe and signaling growing upside potential. 🔍 Weekly structure highlights: 🔹 Price is firmly challenging the $3.25 weekly cup level 🔹 Strong recovery from long term lows with clear higher-low structure 🔹 Momentum accelerating as price moves through the base 🎯 Upside levels in focus as momentum builds: 📈 $3.65 📈 $4.00 📈 $4.40 📈 $4.90 📈 $5.43 📈 $5.90–$6.50 zone A sustained push through $3.25 on the weekly sets the stage for a broader move higher, with the chart offering clear expansion potential into upper resistance bands. Positive market reaction to recent breakthroughs reinforces HYFT’s positioning as a potential platform winner in the multi billion dollar influenza vaccine market. Communicated Disclaimer: https://bit.ly/45yIR8a Sector Peers: $IGMS $ANTX $CABA $ENTX

🧬 $HYFT Targets What Influenza Can’t Change MindWalk Holdings Corp. is a Bio-Native AI company using its patented HYFT Deep Data technology to uncover biological constraints and enable next generation vaccine and therapeutic design. This morning, MindWalk announced a major advance in its universal influenza program, identifying a functional constraint that persists across influenza viruses despite constant mutation. ➡️Not sequence-base, targets biophysical requirements ➡️Focuses on what influenza cannot change and still infect ➡️Enables rational universal vaccine design Confirmed across: ➡️Influenza A & B ➡️H3N2 (Subclade K) ➡️Avian H5, H7, H9 ➡️Swine H1N1 With flu activity at multi decade highs and a multi-billion-dollar vaccine market, HYFT is positioning for platform validation, partnerships, and long-term value creation. Communicated Disclaimer: https://bit.ly/45yIR8a Sector Peers: $CRSP $ABCL $ONC $ENTX

$ENTX Nice summary: https://www.encodelp.com/coverage-universe/pre-jpm26/

$ENTX Several good days lately. Hopefully they have announcement of partnership for EB-613 going into P3.

$ENTX hopefully we can stack together a few more good days! + insider trading info and great pipeline.

$ENTX https://www.bioreview.com/entera-bios-next-to-clinic-program-looks-to-transform-a-hormone-therapy-that-patients-rely-on-for-life/

$ENTX SOMEONE IS ASKING 8,000 @ $8.88

$ENTX huge trade just posted